CME

Host: Farrukh Abbas, MD

Guest: Megan Conroy, MD, MA(Ed), FCCP

Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more.

Since the time of this recording, the FDA has recently approved dupilumab as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with type 2 inflammation.

Guest: Manesh R. Patel, MD

Expert faculty discuss the critical role of cardiac and inflammatory biomarkers in assessing myocardial damage, predicting risk, and monitoring treatment response. The program also explores emerging therapeutic strategies aimed at mitigating ischemia-reperfusion injury (IRI) and reducing the risk of adverse cardiovascular events. Join Drs. Manesh Patel and Deepak Bhatt as they address the long-term consequences of IRI, including the development of heart failure and increased cardiovascular mortality. By providing a comprehensive overview of IRI, this program aims to enhance understanding and inform clinical practice.

Guest: Manesh R. Patel, MD

Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Expert faculty discuss the critical role of cardiac and inflammatory biomarkers in assessing myocardial damage, predicting risk, and monitoring treatment response. The program also explores emerging therapeutic strategies aimed at mitigating ischemia-reperfusion injury (IRI) and reducing the risk of adverse cardiovascular events. Join Drs. Manesh Patel and Deepak Bhatt as they address the long-term consequences of IRI, including the development of heart failure and increased cardiovascular mortality. By providing a comprehensive overview of IRI, this program aims to enhance understanding and inform clinical practice.

Guest: Manesh R. Patel, MD

Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Expert faculty discuss the critical role of cardiac and inflammatory biomarkers in assessing myocardial damage, predicting risk, and monitoring treatment response. The program also explores emerging therapeutic strategies aimed at mitigating ischemia-reperfusion injury (IRI) and reducing the risk of adverse cardiovascular events. Join Drs. Manesh Patel and Deepak Bhatt as they address the long-term consequences of IRI, including the development of heart failure and increased cardiovascular mortality. By providing a comprehensive overview of IRI, this program aims to enhance understanding and inform clinical practice.

Guest: Manesh R. Patel, MD

Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Expert faculty discuss the critical role of cardiac and inflammatory biomarkers in assessing myocardial damage, predicting risk, and monitoring treatment response. The program also explores emerging therapeutic strategies aimed at mitigating ischemia-reperfusion injury (IRI) and reducing the risk of adverse cardiovascular events. Join Drs. Manesh Patel and Deepak Bhatt as they address the long-term consequences of IRI, including the development of heart failure and increased cardiovascular mortality. By providing a comprehensive overview of IRI, this program aims to enhance understanding and inform clinical practice.

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO

Guest: Jyoti Patel, MD

The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.

Guest: Fatemeh Rajaii, MD, PhD

Guest: Selina McGee, OD, FAAO

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Host: Prem S. Subramanian, MD, PhD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Host: Prem S. Subramanian, MD, PhD

Guest: Fatemeh Rajaii, MD, PhD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Guest: Selina McGee, OD, FAAO

Guest: Terry J. Smith, MD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.